[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"scars\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:scars":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,39,69,91,114],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":4,"briefSummary":20,"conditions":21,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100581444","pmcf-investigation-of-medical-device-chitocare-medical-100581444",false,"NCT06850389","PMCF Investigation of Medical Device ChitoCare® Medical","The inclusion criteria are fully according to indications:\n\n* Gel - scars, conditions after dermatosurgical procedures, dermatitis, acne\n* Spray - conditions after dermatosurgical procedures, dermatitis, acne\n\nThe criteria for exclusion are fully according to contraindications:\n\n* Allergy to any of the ingredients of the product","ALL",{"count":17,"type":18},214,"ESTIMATED","OBSERVATIONAL","This is a post-marketing observational clinical investigation conducted as part of the post-market clinical follow-up of ChitoCare® Medical, aimed to confirm safety and efficacy according to the requirements of Regulation (EU) 2017\u002F745 of the European Parliament and of the Council of 5 April 2017 on medical devices, for the following indications:\n\nGel - scars, conditions after dermatosurgical procedures, dermatitis, acne\n\nSpray - conditions after dermatosurgical procedures, dermatitis, acne",[22,23,24,25],"Dermatitis","Acne","Conditions After Dematosurgical Procedures","Scars","RECRUITING","2025-08-13",{"date":29,"type":30},"2025-08-17","ACTUAL",{"date":32,"type":30},"2025-06-11",{"date":34,"type":18},"2025-12",{"name":36,"class":37},"Primex ehf","INDUSTRY",2,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":45,"sex":15,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":68},"100582846","avava-miria-general-use-100582846","NCT06868615","AVAVA MIRIA General Use","Inclusion Criteria:\n\n1. Male or female subjects between 18 to 70 years of age.\n2. Dermatologic condition that can be addressed by the laser, including but not limited to:\n\n   1. Wrinkles\n   2. Scars\n   3. Acne Scars\n   4. Active Acne\n   5. Dyschromia\n   6. Cutaneous Lesions such as Age or Sun Spots\n   7. Melasma\n   8. Laxity\n3. Willingness to have digital photographs taken of treatment area(s) and agreement with use of photographs for presentation, educational, or marketing purposes.\n4. Willingness to comply with the following during the study, including the follow-up period:\n\n   1. maintain consistent skin care regimen on treated areas.\n   2. cover treated areas or have very limited sun exposure and, if requested, use an approved sunscreen of SPF 50 or higher.\n   3. refrain from using systemic corticosteroids, according to Investigator discretion.\n   4. refrain from using topical corticosteroids, retinoids, or prescription skin-lightening medications on the treated areas, according to Investigator discretion.\n   5. refrain from any other procedures in the treatment areas.\n5. Willingness and ability to comply with study instructions and return for required visits.\n6. Subject has read and signed a written informed consent form.\n7. Subject lives within 50 miles of study site.\n8. Willingness to shave hair in intended treatment area\n\nExclusion Criteria:\n\n1. Skin pathology or condition that could interfere with evaluation of the study procedure, e.g.,\n2. Systemic treatment prescribed within previous 6 months (e.g., oral medication such as isotretinoin)\n3. Surgical treatment in the target areas within previous 6 months (e.g., laser surgery)\n4. Active vitiligo, psoriasis, or eczema in the treatment area\n5. Injection of dermal filler in the target areas within previous 1 month (e.g., collagen, hyaluronic acid filler)\n6. Cosmetic procedures in the target areas within prior 3 months (e.g., laser, microdermabrasion, skin peel)\n7. Topical treatment applied to target areas within the previous 1 month or according to Investigator discretion.\n8. Active suntan and unable or unlikely to refrain from tanning within the follow-up period.\n9. Artificial tanning in the target areas within the previous 1 month (e.g., spray, lotion, tanning bed) or intention to use artificial tanning within the follow-up period.\n10. Active localized or systemic infection, or an open wound in area being treated.\n11. Lesions in the treatment areas suspicious for malignancy (skin cancer, melanoma)\n12. History of abnormal wound healing or abnormal scarring (e.g., hypertrophic or keloid)\n13. History of connective tissue disease, such as lupus or scleroderma.\n14. Any use of medication that is known to increase sensitivity to light according to Investigator's discretion (e.g., topicals that produce sensitivity to light may be used in areas other than the target area).\n15. History of gold therapy.\n16. History of disease stimulated by heat, such as recurrent herpes simplex or herpes zoster (shingles) in the treatment area, unless treatment is conducted following a prophylactic regimen.\n17. History of radiation to the treatment area or currently undergoing systemic chemotherapy for the treatment of cancer.\n18. For Female: Pregnancy or lactation, or intent to become pregnant within the study period.\n19. Significant uncontrolled concurrent illness, such as diabetes mellitus or cardiovascular disease, e.g., uncontrolled hypertension.\n20. History of immunosuppression\u002Fimmune deficiency disorder or currently using immunosuppressive medications.\n21. Current enrollment in a clinical study of any other unapproved investigational drug or device\n22. Any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect response or participation in this clinical study, or would pose an unacceptable risk to the subject.",true,"18 Years","70 Years",{"count":49,"type":18},200,"INTERVENTIONAL",[52],"NA","A general protocol to treat a variety of dermatologic conditions and collect patient feedback.\n\nPrimary outcome is the collection and analysis of patient questionnaires related to the overall experience of the device treatment. Secondary outcome measures include physician and subject evaluations in regards to improvement seen in the device as well as assessment of side effects.",[23,55,25,56,57,58],"Acne Scars - Mixed Atrophic and Hypertrophic","Wrinkle","Pigment; Lesion","Skin Texture Disorder","2025-03-06",{"date":61,"type":30},"2025-03-11",{"date":63,"type":30},"2024-09-11",{"date":65,"type":18},"2027-12-30",{"name":67,"class":37},"AVAVA, Inc.",1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":15,"minAge":46,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":50,"phases":78,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":68},"100559605","autologous-nanofat-grafting-by-injection-versus-with-microneedling-in-post-burn-and-traumatic-atrophic-scars-100559605","NCT06566300","Autologous Nanofat Grafting by Injection Versus With Microneedling in Post-burn and Traumatic Atrophic Scars","Inclusion Criteria:\n\n* 1\\. Males and females between 18-60 years old. 2. Post-burn or traumatic atrophic scar \\> 6 months duration (16). 3. Patients not receiving any treatments for the scar within the past 3 months.\n\nExclusion Criteria:\n\n* 1\\. Patients with contractures, hypertrophic and keloid scars. 2. Patients with history of bleeding disorders or coagulopathy, or on anticoagulant therpy.\n\n  3\\. Diabetes and other systemic diseases that may be complicated by the procedure.\n\n  4\\. Pregnant and lactating females. 5. BMI less than 18.5 6. Patients with scars at the donor site","60 Years",{"count":77,"type":18},30,[52],"This study aims to evaluate the efficiency autologous nanofat injection versus autologous nanofat delivered by microneedling in management of post burn atrophic and traumatic scars.",[25],"2024-11-02",{"date":83,"type":30},"2024-11-05",{"date":85,"type":30},"2024-11-01",{"date":87,"type":18},"2025-02",{"name":89,"class":90},"Alexandria University","OTHER",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":15,"minAge":97,"maxAge":75,"enrollmentInfo":98,"targetDuration":4,"studyType":50,"phases":100,"briefSummary":101,"conditions":102,"keywords":104,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":68},"100517725","microneedling-with-regular-insulin-versus-microneedling-alone-in-treatment-of-atrophic-scars-100517725","NCT06021275","Microneedling With Regular Insulin Versus Microneedling Alone in Treatment of Atrophic Scars","Inclusion Criteria:\n\n1. Patients aged 12 to 60 years\n2. Atrophic scars (traumatic or surgical)\n3. Completely healed scars\n\nExclusion Criteria:\n\n1. Patients with a tendency or history of hypertrophic or keloidal scars\n2. Patients who received treatment for their scar in the past 3 months\n3. Diabetic patients or those with a history of Dysglycemia\n4. Pregnant, or lactating females\n5. Patients with active infection at the site of scar\n6. Patients currently receiving isotretinoin treatment or in the past month","12 Years",{"count":99,"type":18},40,[52],"Recently, few studies have attempted to test the regenerative effects of human insulin application by microneedling on atrophic scars versus other topical preparations. However, the scars were limited etiologically to acne scars. In addition, a lack of inclusion of a control group instead of comparing topical preparations with insulin was also a limitation to these studies. A control group consisting of microneedling alone would have served as a better comparison in order to determine whether the effects of microneedling are augmented by topical protein-rich preparations.",[25,103],"Insulin",[103,105],"scars","2024-07-27",{"date":108,"type":30},"2024-07-30",{"date":110,"type":30},"2023-10-01",{"date":112,"type":18},"2024-12",{"name":89,"class":90},{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":45,"sex":15,"minAge":46,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":50,"phases":122,"briefSummary":123,"conditions":124,"keywords":125,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":68},"100345771","study-to-evaluate-the-efficacy-of-a-micro-coring-device-for-the-treatment-of-scars-of-the-cytrellis-micro-coring-device-for-the-treatment-of-scars-100345771","NCT03782038","Study to Evaluate the Efficacy of a Micro Coring Device for the Treatment of Scars of the Cytrellis Micro-Coring Device for the Treatment of Scars","A Prospective, Multi-center, Pilot Study to Evaluate the Safety and Efficacy of the Cytrellis Micro-Coring Device for the Treatment of Scars","Inclusion Criteria:\n\n* 18 years of age or older\n* Fitzpatrick scale I-VI.\n* Any type of scar except for keloid scars\n* Able to provide written informed consent, understand and willing to comply with study related procedures and follow-ups.\n\nExclusion Criteria:\n\n* Previous treatment of the scar tissue within last 6 months.\n* Silicone, fat, collagen or synthetic material in the treatment area.\n* History of keloid formation.\n* Active smokers (smoking more than ½ pack per day) or having quit smoking (½ pack per day) for less than 3 months.\n* Active, chronic, or recurrent infection.\n* Compromised immune system (e.g. diabetes).\n* Hypersensitivity to analgesic agents.\n* Co-morbid condition that could limit ability to participate in the study or to comply with follow-up requirements.\n* Pregnant or breastfeeding.\n* Any issue that, at the discretion of the investigator, would contra-indicate the subject's participation.\n* Any medication that may cause bleeding such as anticoagulants.\n* Allergy to lidocaine and\u002For epinephrine",{"count":77,"type":18},[52],"A study to evaluate the safety and effectiveness of a micro coring device for the treatment of scars.",[25],[126,127,128],"Acne Scars","Stretchmarks","Surgical Scars","2018-12-19",{"date":131,"type":30},"2018-12-21",{"date":133,"type":30},"2018-09-13",{"date":135,"type":18},"2019-11-21",{"name":137,"class":37},"Cytrellis Biosystems, Inc."]